Protection against focal ischemic injury to the brain by trans-sodium crocetinate

Laboratory investigation

Hiroaki Manabe, M.D.,1 David O. Okonkwo, M.D., Ph.D.,1,2 John L. Gainer, Ph.D.,3 Ryon H. Clarke, B.A.,1,4 and Kevin S. Lee, Ph.D.1,2

Departments of 1Neuroscience, 2Neurological Surgery, and 3Chemical Engineering, and 4Neuroscience Graduate Program, University of Virginia, Charlottesville, Virginia

Object. Ischemic injury is a potential complication in a variety of surgical procedures and is a particular impediment to the success of surgeries involving highly vulnerable neural tissue. One approach to limiting this form of injury is to enhance metabolic supply to the affected tissue. Trans-sodium crocetinate (TSC) is a carotenoid compound that has been shown to increase tissue oxygenation by facilitating the diffusivity of small molecules, such as oxygen and glucose. The present study examined the ability of TSC to modify oxygenation in ischemic neural tissue and tested the potential neuroprotective effects of TSC in permanent and temporary models of focal cerebral ischemia.

Methods. Adult male rats (330–370 g) were subjected to either permanent or temporary focal ischemia by simultaneous occlusion of both common carotid arteries and the left middle cerebral artery (3-vessel occlusion [3-VO]). Using the permanent ischemia paradigm, TSC was administered intravenously beginning 10 minutes after the onset of ischemia at 1 of 8 dosages, ranging from 0.023 to 4.580 mg/kg. Cerebral infarct volume was measured 24 hours after the onset of ischemia. The effect of TSC on infarct volume was also tested after temporary (2-hour) ischemia using a dosage of 0.092 mg/kg. In other animals undergoing temporary ischemia, tissue oxygenation was monitored in the ischemic penumbra using a Licox probe.

Results. Administration of TSC reduced infarct volume in a dose-dependent manner in the permanent ischemia model, achieving statistical significance at dosages ranging from 0.046 to 0.229 mg/kg. The most effective dosage of TSC in the permanent ischemia experiment (0.092 mg/kg) was further tested using a temporary (2-hour) ischemia paradigm. Infarct volume was reduced significantly by TSC in this ischemia-reperfusion model as well. Recordings of oxygen levels in the ischemic penumbra of the temporary ischemia model showed that TSC increased tissue oxygenation during vascular occlusion, but reduced the oxygen overshoot (hyperoxygenation) that occurs upon reperfusion.

Conclusions. The novel carotenoid compound TSC exerts a neuroprotective influence against permanent and temporary ischemic injury when administered soon after the onset of ischemia. The protective mechanism of TSC remains to be confirmed; however, the permissive effect of TSC on the diffusivity of small molecules is a plausible mechanism based on the observed increase in tissue oxygenation in the ischemic penumbra. This represents a form of protection based on “metabolic reflow” that can occur under conditions of partial vascular perfusion. It is particularly noteworthy that TSC could conceivably limit the progression of a wide variety of cellular injury mechanisms by blunting the ischemic challenge to the brain. (DOI: 10.3171/2009.10.JNS09562)

Key Words • trans-sodium crocetinate • focal ischemia • oxygen delivery • neuroprotection • metabolic reflow

Focal ischemia is an anticipated consequence of certain neurosurgical procedures and a common complication of others. Many attempts to limit the progression of intraoperative ischemic brain injury have focused on the suppression of metabolic demand or the inhibition of cellular injury cascades. These strategies share a common goal of limiting the cellular/molecular consequences that result from a reduction in the supply of metabolic substrates. An alternative approach to limiting ischemic tissue damage is to enhance metabolic supply in areas that retain partial perfusion. One such strategy, which has been tested in a variety of models of brain injury, is therapeutic hyperoxia. Hyperbaric hyperoxia has shown beneficial effects in experimental models of intraoperative ischemia, stroke, and traumatic brain injury. Clinical studies of hyperbaric hyperoxia have been less conclusive, but such studies have been hampered by small sample sizes and relatively long delays prior to initiating...
Neuroprotection by TSC

treatment. More recent studies indicate that normobaric hyperoxia can also improve outcomes in experimental models of cerebral ischemia and injury. Moreover, early-stage human studies using normobaric hyperoxia have shown promising results in treating cerebral injury. However, significant controversy as to the efficacy of normobaric hyperoxia remains, as highlighted in recent commentaries on the progress in this field. Despite this controversy, the potential for such therapies to ameliorate multiple forms of CNS injury for which there are no or inadequate medical countermeasures continues to warrant careful experimental and clinical assessment.

When considering the challenges of ischemic conditions, it is important to keep in mind that the delivery of metabolic substrates from the blood to tissue involves a series of resistances. A limiting resistance in this series is diffusion through the plasma boundary layer. As described by Fick’s law, oxygen delivery is directly proportional to both the oxygen concentration gradient and diffusivity, the latter being a measure of the ease with which a compound diffuses through a medium. It is thus possible to enhance substrate delivery to tissue not only through hyperoxia, but also by enhancing the diffusion of substrates through the plasma boundary layer. One compound that has been shown to increase the diffusion rate of oxygen through plasma is trans-sodium crocetinate (TSC). Trans-sodium crocetinate is a carotenoid compound (vitamin A analog) whose ability to enhance diffusivity in plasma is attributable to an alteration in the intermolecular spacing in aqueous solutions. Although the baseline diffusivities for oxygen and glucose through aqueous media are different, they both increase by a similar percentage in the presence of TSC. Thus, TSC does not affect oxygen or glucose directly. Rather, TSC can increase hydrogen bonding of neighboring water molecules, a process known as “structure-building,” which reduces the resistance to the diffusion of small molecules such as oxygen and glucose.

The present study examined the ability of TSC to modify tissue oxygenation in the ischemic brain. In addition, the potential impact of TSC on tissue injury was studied in both permanent and temporary models of focal ischemia.

Methods

General Procedures

All procedures were approved by the University of Virginia Animal Care and Use Committee. Adult male Sprague-Dawley rats (330–370 g) were initially anesthetized in a plastic chamber with 4% halothane. Once they were anesthetized, orotracheal intubation was performed with the tube connected to a ventilator (Rodent Ventilator model 638, Harvard Apparatus) and FiO2 (fraction of inspired oxygen) was standardized at 50% for all experiments. The right femoral artery was cannulated for BP monitoring and repeated blood gas analysis (348 Blood Gas Analyzer, Bayer HealthCare). Rectal temperature was monitored continuously and maintained at 37°C with a heating lamp. Inspired halothane was controlled around 1.5% to maintain anesthesia and keep the MABP at approximately 110 mm Hg.

Both CCAs were exposed and a 5–0 monofilament polypropylene suture was passed through a polyethylene tube to create snare, which were loosely placed around each CCA for subsequent occlusion. The MCA was exposed according to the method of Hiramatsu et al. Briefly, animals were placed in a right decubitus position and a 1.5-cm incision was made between the left margin of the orbit and the tragus. The exposed temporal muscle was dissected from the cranium to reveal the infratemporal bone. After removal of the zygomatic arch, a craniectomy was made slightly anterior to the foramen ovale by using an electric drill under a surgical microscope. The dura mater was opened carefully and reflected using a 30-gauge needle, thus exposing the MCA bifurcation.

Focal ischemia was established by clipping (Sundt AVM microclip No. 1, Codman & Shurtleff, Inc.) the MCA at a point distal to the origin of the lenticulostriate arteries. The polypropylene suture loops around the CCAs were closed at the same time to complete the 3-vessel occlusion (3-VO). Loss of blood flow was confirmed visually with the surgical microscope, and occlusion of the MCA and both CCAs was maintained for 24 hours in the permanent ischemia protocol. In the transient ischemia protocol, the microclip blocking the MCA and polypropylene snare around both CCAs were removed 2 hours after onset of ischemia and reflow was confirmed visually by observation through the surgical microscope. Animals were anesthetized during the surgical procedure but were permitted to recover from anesthesia postoperatively. The animals were monitored carefully for 1 hour after the surgery and then returned to the vivarium.

Measurement of Infarct Volume

Twenty-four hours after the onset of ischemia, animals were anesthetized with an overdose of pentobarbital and killed by decapitation. The brains were removed rapidly and coronal sections (2-mm thick) were cut with a McIlwain tissue chopper. The sections were stained with 2% 2,3,5-triphenyltetrazolium chloride (TTC) in phosphate-buffered saline for 5 minutes at 37°C and then placed in 4% paraformaldehyde solution.

Infarct volume was calculated by summing the infarct areas in individual sections, as measured using image analysis software (Scion Image Beta 4.02, Scion Corp.). In addition, the areas of the hemispheres ipsilateral and contralateral to the occluded MCA were measured, and the total volume of each hemisphere was calculated in a similar manner. The actual infarct volume, adjusted for swelling, was calculated using the following formula: actual infarct volume = total infarct volume × (contralateral hemisphere volume/ipsilateral hemisphere volume). The values presented below are the actual infarct volumes.

Statistical comparisons for 3 groups or more used a 1-way ANOVA followed by the LSD post hoc test. The Student t-test was used for comparisons between 2 groups. A probability value of < 0.05 was considered to be statistically significant.
Experiment 1: Effect of TSC on Cerebral Infarction in a Model of Permanent Focal Ischemia

Ten minutes after permanent 3-VO was established, animals were treated with vehicle or 1 of 8 different dosages of TSC (0.023, 0.046, 0.092, 0.229, 0.458, 0.916, 2.29, or 4.58 mg/kg). Seven animals were included in each group. Vehicle or TSC (in equivalent volumes) was administered via the femoral vein using a “bolus-infusion-bolus” treatment paradigm. Ten minutes after the onset of ischemia, a bolus injection of 0.1 ml was administered, followed by continuous infusion at 0.01 ml per minute for 60 minutes. Thirty minutes after the cessation of infusion, another 0.1 ml was injected. This treatment protocol was based on previous evidence demonstrating TSC-induced elevation of tissue oxygenation in the brain. All of the dosages reported herein reflect the total dosage of TSC administered during the 2 bolus injections and the infusion period. Animals were killed 24 hours after the onset of ischemia and infarct volume was calculated as described above.

Experiment 2: Effect of TSC on Cerebral Infarction in a Model of Transient Focal Ischemia

The most effective dosage of TSC, as determined from the dose-response curve generated in Experiment 1, was used to test the effect of TSC in a model of transient focal ischemia. Trans-sodium crocetinate (0.092 mg/kg) or vehicle (6 animals per group) was administered using the same bolus-infusion-bolus treatment protocol beginning 10 minutes after the onset of ischemia, as in Experiment 1. Reflow was established after 2 hours of 3-VO and animals were killed 24 hours after the onset of ischemia—that is, 22 hours after reflow. Cerebral infarct volume was determined as described above.

Experiment 3: Effect of TSC on Brain Tissue Oxygenation in a Model of Transient Focal Ischemia

This experiment assessed the effect of TSC on brain tissue oxygenation during ischemia. The preparative stages of the 3-VO surgery were performed as described earlier until the point of clipping the arteries. The skull of the rat was then secured to a stereotactic frame. A midline scalp incision was made and a small craniotomy was performed over the region of the ischemic penumbra (0.5 mm posterior to bregma and 2.5 mm lateral to the midline). These coordinates were used based on our previous studies in which distinct core and penumbra regions were defined with the 3-VO model. An oxygen-sensing probe (Licox, Integra Neuroscience) was lowered stereotactically into the neocortex (2.5 mm deep) to measure brain PO2. An equilibration period of at least 60 minutes was allowed for the Licox probe, after which baseline values were recorded for at least 15 minutes. Once a stable baseline was established, the vessels for the 3-VO were blocked. Either TSC (0.092 mg/kg; 5 animals) or vehicle (7 animals) was administered starting 10 minutes after the onset of ischemia using the standard bolus-infusion-bolus treatment protocol. Reflow was established after 2 hours of 3-VO and tissue oxygen recordings were terminated approximately 15 minutes thereafter. For the quantitative analyses, the recorded tissue oxygen levels were normalized for each animal to their preischemic baseline to facilitate comparisons among animals. Animals were killed at the end of this recording period. The animals in these groups were not used for the assessment of infarct volume because of the additionally invasive nature of the oxygen recording procedure in the ischemic tissue.

Results

Experiment 1: Effect of TSC on Cerebral Infarction in a Model of Permanent Focal Ischemia

Treatment with TSC beginning 10 minutes after the onset of ischemia produced a dose-dependent neuroprotective effect, reducing the volume of cerebral infarction in the model of permanent focal cerebral ischemia (Fig. 1). A biphasic (U-shaped) reduction in infarct volume was observed, with intermediate dosages of TSC providing the greatest protective effect. The reductions in infarct volume achieved statistical significance at dosages ranging from 0.023 to 0.229 mg/kg. A maximal protective effect, representing a reduction in infarct volume of approximately 60%, was achieved at a dosage of 0.092 mg/kg (Fig. 1). Examples of the cerebral infaracts observed in the Vehicle Group and the group treated with 0.092 mg/kg TSC are shown in Fig. 2. Comparisons between matching section levels show a substantial reduction in infarct size in the TSC-treated animal. Physiological parameters were monitored 1) before ischemia, 2) during ischemia and TSC infusion, and 3) during ischemia after the cessation of TSC treatment (Table 1). No significant differences among groups were observed for the physiological parameters, which included MABP, heart rate, blood pH, blood PCO2, and blood PO2.

Experiment 2: Effect of TSC on Cerebral Infarction in a Model of Transient Focal Ischemia

The effect of TSC was next tested in a model of ischemia. The bar graph shows group means and SEs for the vehicle- and TSC-treated animals (7 rats per group). The volume of cerebral infarction was reduced by TSC in a dose-dependent manner, characterized by a U-shaped curve. This protective action achieved statistical significance at TSC dosages ranging from 0.023 to 0.229 mg/kg, with a maximal protective effect being achieved at 0.092 mg/kg. * p < 0.05, 1-way ANOVA and the LSD post hoc test.
Neuroprotection by TSC

Fig. 2. Examples of cerebral infarcts in vehicle-treated and TSC-treated animals. Serial coronal sections obtained from a vehicle-treated animal and a TSC-treated animal (0.092 mg/kg) are shown. Sections were stained with tetrazolium chloride for the detection of infarcted tissue. Areas of tissue infarction appear white in these sections, while the healthy tissue appears red. The infarct size is substantially smaller in the animal from the TSC-treated group.

Ema-reperfusion involving 2 hours of ischemia followed by 22 hours of reperfusion. The dosage of TSC providing an optimal neuroprotective effect in Experiment 1 (0.092 mg/kg) was used, with treatment being initiated 10 minutes after the onset of ischemia. Treatment with TSC significantly reduced the volume of cerebral infarction. The volume of infarction in the TSC-treated group was reduced by approximately 45% as compared with that in the vehicle-treated group (Fig. 3). Physiological parameters monitored 1) before ischemia, 2) during ischemia and TSC treatment, and 3) after reperfusion are shown in Table 2. No significant differences among groups were observed for the physiological parameters.

Experiment 3: Effect of TSC on Brain Tissue Oxygenation in a Model of Transient Focal Ischemia

An enhancement of brain tissue oxygenation by TSC has been demonstrated previously under nonpathological circumstances in the presence of elevated FiO₂, however, the impact of TSC on tissue oxygenation in ischemic brain has not been evaluated. In Experiment 3, tissue oxygenation was monitored in the ischemic penumbra of the 3-VO model in animals treated with TSC or vehicle. Animals underwent transient focal ischemia as in the previous experiment and tissue oxygen levels were monitored with a Licox probe. Tissue oxygen levels were reduced substantially in both groups of animals in response to vascular occlusion (Fig. 4). Treatment with TSC (0.092 mg/kg) beginning 10 minutes after the onset of ischemia resulted in a progressive and significant increase in tissue oxygenation, as compared with vehicle-treated controls. Within 10 minutes of administering TSC, the levels of penumbral tissue oxygenation began to rise, and during the course of the recordings TSC reversed the intensity of oxygen deprivation by approximately 50%. It is also noteworthy that upon reflow the oxygen overshoot (reperfusion hyperoxia) was less pronounced in the TSC-treated group. Thus, the intensity of hypoxia during vascular occlusion was reduced, while reperfusion hyperoxia was attenuated in the TSC-treated group. As in the previous experiment, physiological parameters did not differ between groups (data not shown).

Discussion

Therapeutic strategies designed to attenuate ischemic injury to the nervous system have generally focused on limiting the induction and/or progression of cellular mechanisms of injury. These strategies have taken various forms, but they commonly involve either the suppression of metabolic activity or the inhibition of specific injury cascades. An alternative approach has been to enhance metabolic supply to areas of partial perfusion to sustain essential cellular functions. This approach typically entails an increase in systemic oxygen supply (hyperoxegenation) under hyperbaric and more recently normobaric conditions. Each of these strategies holds considerable promise and warrants continued and careful development.

The current study describes a novel therapeutic approach that is related conceptually to hyperoxygenation therapy. Trans-sodium crocetinate is a modified carotenoid compound that is capable of enhancing the diffusivity of small molecules in aqueous solutions. This compound and its parent compound crocetin have previously been shown to increase tissue oxygenation in multiple organ systems. In a model of hemorrhagic shock, TSC both improved oxygen consumption and increased survival. Observations presented herein support these previous findings by demonstrating that TSC treatment increases tissue oxygen levels in an area of partial perfusion in the brain. To our knowledge, this is the first evidence of a medicinally induced increase in tissue oxygenation in the penumbra of a focal ischemic event. While the mechanistic underpinnings of enhanced tissue oxygenation were not the subject of the current study, previous studies demonstrate that TSC increases hydrogen bonding among water molecules, leading to a reduction in chaos in the aqueous solution. This process is known as “structure-building” and in aqueous solutions (for example, plasma and interstitial fluids) increased structure can facilitate the diffusivity of small molecules, including oxygen and glucose. Inasmuch as the plasma phase is a critical site of resistance for the delivery of blood-borne oxygen to tissue, it is postulated that enhanced diffusivity of metabolic substrates from the vasculature contributes to the TSC-induced increase in tissue oxygenation in the ischemic penumbra.

A central goal of the current study was to evaluate the potential protective actions of TSC against ischemic injury to the brain. In a rat model of permanent focal ischemia, TSC was effective in reducing infarct volume when treatment was initiated soon after the onset of ischemia. This effect was dose dependent, with significant protection in the dosage range of 0.023–0.229 mg/kg and optimal protection at a dosage of 0.092 mg/kg TSC. The mechanism underlying the reduced efficacy of TSC at the highest dosages is at present unknown and remains a matter for future investigation. The protective effect of TSC at its optimal
dosage represented a reduction in infarct volume of approximately 60%, which rivals maximal protective effects of other interventions (for example, hypothermia) observed in the 3-vessel model of focal ischemia.18

A key a priori concern about any therapy involving increased oxygenation is that elevated levels of tissue oxygen could aggravate outcomes during the reperfusion phase that follows transient ischemia. Considerable evidence supports the concept that an oxidative burst and free radical generation play critical roles in ischemia-reperfusion injury. Reperfusion in the presence of elevated tissue oxygen could conceivably amplify damaging effects of oxidative injury. This issue was evaluated using 2 approaches. First, the hyperoxia response during postischemic reperfusion was examined in TSC-treated animals. Second, the impact of TSC on cerebral infarction was assessed subsequent to ischemia-reperfusion. Rather than potentiating postischemic hyperoxia, treatment with TSC actually blunted postischemic hyperoxia. We speculate that this reduction in the reperfusion-hyperoxia reflects a healthier state of the penumbral tissue, owing to metabolic substrate supplementation produced by TSC during ischemia.

### TABLE 1: Physiological parameters in animals from the permanent (24-hour) ischemia experiment (Experiment 1)*

<table>
<thead>
<tr>
<th>Dosage &amp; Timing of Measurements</th>
<th>MABP (mm Hg)</th>
<th>HR (beats/min)</th>
<th>pH</th>
<th>PCO₂ (mm Hg)</th>
<th>PO₂ (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vehicle</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>122.9 ± 4.2</td>
<td>353.4 ± 8.8</td>
<td>7.453 ± 0.020</td>
<td>29.1 ± 2.8</td>
<td>168.0 ± 12.3</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>122.8 ± 2.8</td>
<td>377.2 ± 11.4</td>
<td>7.446 ± 0.022</td>
<td>29.2 ± 2.5</td>
<td>175.8 ± 10.6</td>
</tr>
<tr>
<td>after infusion</td>
<td>125.8 ± 2.2</td>
<td>385.6 ± 6.5</td>
<td>7.427 ± 0.026</td>
<td>31.3 ± 2.2</td>
<td>176.1 ± 9.2</td>
</tr>
<tr>
<td><strong>0.023 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>121.1 ± 3.7</td>
<td>376.6 ± 7.2</td>
<td>7.470 ± 0.019</td>
<td>28.2 ± 1.8</td>
<td>178.6 ± 8.1</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>119.6 ± 4.0</td>
<td>394.7 ± 10.8</td>
<td>7.474 ± 0.011</td>
<td>31.9 ± 0.7</td>
<td>178.5 ± 7.9</td>
</tr>
<tr>
<td>after infusion</td>
<td>124.0 ± 5.1</td>
<td>392.2 ± 10.2</td>
<td>7.458 ± 0.018</td>
<td>28.5 ± 2.0</td>
<td>179.3 ± 9.4</td>
</tr>
<tr>
<td><strong>0.046 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>121.6 ± 3.2</td>
<td>369.1 ± 5.6</td>
<td>7.455 ± 0.016</td>
<td>32.0 ± 2.6</td>
<td>190.2 ± 7.1</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>123.6 ± 3.4</td>
<td>386.3 ± 12.5</td>
<td>7.457 ± 0.017</td>
<td>31.2 ± 2.3</td>
<td>176.8 ± 6.3</td>
</tr>
<tr>
<td>after infusion</td>
<td>119.5 ± 1.7</td>
<td>377.3 ± 14.4</td>
<td>7.460 ± 0.017</td>
<td>32.1 ± 2.8</td>
<td>168.6 ± 7.5</td>
</tr>
<tr>
<td><strong>0.092 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>125.0 ± 6.8</td>
<td>364.6 ± 8.0</td>
<td>7.480 ± 0.015</td>
<td>31.5 ± 2.6</td>
<td>192.5 ± 7.0</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>124.4 ± 4.1</td>
<td>386.4 ± 13.9</td>
<td>7.451 ± 0.016</td>
<td>30.6 ± 1.5</td>
<td>183.3 ± 6.8</td>
</tr>
<tr>
<td>after infusion</td>
<td>122.8 ± 3.3</td>
<td>376.4 ± 15.8</td>
<td>7.426 ± 0.007</td>
<td>33.8 ± 1.6</td>
<td>168.2 ± 8.8</td>
</tr>
<tr>
<td><strong>0.230 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>116.3 ± 5.4</td>
<td>378.3 ± 9.8</td>
<td>7.474 ± 0.013</td>
<td>30.3 ± 1.5</td>
<td>185.7 ± 9.8</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>121.8 ± 4.3</td>
<td>394.7 ± 4.0</td>
<td>7.461 ± 0.017</td>
<td>30.2 ± 1.5</td>
<td>190.6 ± 9.8</td>
</tr>
<tr>
<td>after infusion</td>
<td>131.3 ± 6.3</td>
<td>397.5 ± 12.1</td>
<td>7.453 ± 0.016</td>
<td>30.4 ± 2.3</td>
<td>187.6 ± 6.4</td>
</tr>
<tr>
<td><strong>0.458 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>117.5 ± 3.4</td>
<td>339.7 ± 17.6</td>
<td>7.457 ± 0.014</td>
<td>30.5 ± 2.1</td>
<td>167.5 ± 12.0</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>128.5 ± 6.7</td>
<td>357.3 ± 18.7</td>
<td>7.433 ± 0.020</td>
<td>29.4 ± 2.6</td>
<td>171.9 ± 11.4</td>
</tr>
<tr>
<td>after infusion</td>
<td>125.2 ± 6.2</td>
<td>355.2 ± 5.9</td>
<td>7.436 ± 0.006</td>
<td>29.7 ± 1.9</td>
<td>174.4 ± 11.2</td>
</tr>
<tr>
<td><strong>0.916 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>113.7 ± 4.4</td>
<td>347.3 ± 6.7</td>
<td>7.432 ± 0.012</td>
<td>31.4 ± 2.3</td>
<td>177.1 ± 7.7</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>115.9 ± 4.0</td>
<td>370.1 ± 10.5</td>
<td>7.447 ± 0.015</td>
<td>32.2 ± 1.7</td>
<td>182.2 ± 6.8</td>
</tr>
<tr>
<td>after infusion</td>
<td>110.7 ± 2.3</td>
<td>364.9 ± 7.1</td>
<td>7.444 ± 0.012</td>
<td>31.6 ± 1.5</td>
<td>184.8 ± 4.9</td>
</tr>
<tr>
<td><strong>2.290 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>118.8 ± 6.7</td>
<td>347.2 ± 7.9</td>
<td>7.451 ± 0.021</td>
<td>31.7 ± 1.8</td>
<td>177.4 ± 6.3</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>119.6 ± 5.3</td>
<td>359.8 ± 8.6</td>
<td>7.435 ± 0.007</td>
<td>32.0 ± 2.2</td>
<td>178.2 ± 4.5</td>
</tr>
<tr>
<td>after infusion</td>
<td>116.8 ± 4.7</td>
<td>356.4 ± 9.1</td>
<td>7.439 ± 0.005</td>
<td>31.6 ± 1.6</td>
<td>182.8 ± 4.6</td>
</tr>
<tr>
<td><strong>4.580 mg/kg TSC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>110.7 ± 2.7</td>
<td>357.0 ± 12.3</td>
<td>7.452 ± 0.017</td>
<td>27.6 ± 2.6</td>
<td>178.8 ± 8.2</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>113.1 ± 2.5</td>
<td>374.3 ± 11.1</td>
<td>7.456 ± 0.015</td>
<td>30.6 ± 2.0</td>
<td>175.4 ± 6.7</td>
</tr>
<tr>
<td>after infusion</td>
<td>111.1 ± 2.3</td>
<td>362.4 ± 12.0</td>
<td>7.443 ± 0.013</td>
<td>31.6 ± 2.5</td>
<td>179.9 ± 4.8</td>
</tr>
</tbody>
</table>

* Values shown are means ± SEs. No significant intergroup differences were observed for MABP, heart rate, blood pH, blood PCO₂, or blood PO₂. Abbreviations: HR = heart rate; pH = blood pH; PCO₂ = blood PCO₂; PO₂ = blood PO₂.
reperfusion. Treatment with TSC reduced cerebral infarct volume by approximately 45% when initiated 10 minutes after the onset of ischemia. Thus, even though the levels of tissue oxygen were elevated at the onset of reperfusion, tissue hyperoxia was blunted during reperfusion, and tissue survival was improved by TSC.

It is important to consider the possibility that TSC could exert its protective actions via mechanism(s) other than the facilitation of small molecule diffusion. For instance, some carotenoid compounds possess free radical scavenging activity, an effect that could provide a protective influence against ischemic neural injury. While TSC is capable of scavenging free radicals, this effect only achieves significance at dosages much higher than those required for TSC to enhance diffusivity and improve survival. Other mechanisms by which TSC could theoretically exert protection include effects on blood flow and/or cellular metabolism. These possibilities have been examined previously with the structurally similar parent compound of TSC, crocetin. However, no significant effects on blood flow,24 oxygen solubility in blood,17 oxyhemoglobin saturation,17 or oxidative phosphorylation17 were observed in response to treatment with crocetin. Although the effect of TSC on blood viscosity has not been studied, it has been shown to produce a slight increase in the viscosity of water,56 which would not be predicted to increase blood flow. Thus, the evidence available to date is inconsistent with the concept that an alternative mechanism to enhanced diffusivity is responsible for the protective actions provided by TSC.

Taken together, the present findings indicate that TSC could be of value for limiting intraoperative ischemic injury or other anticipated forms of ischemic challenge. Based on its presumptive mechanism of action, TSC may be capable of inhibiting a broad range of neural injury mechanisms by reducing both the intensity of the metabolic challenge.

### Table 2: Physiological parameters in animals from the transient (2-hour) ischemia experiment (Experiment 2)*

<table>
<thead>
<tr>
<th>Dosage &amp; Timing of Measurements</th>
<th>MABP (mm Hg)</th>
<th>HR (beats/min)</th>
<th>pH</th>
<th>PCO₂ (mm Hg)</th>
<th>PO₂ (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>vehicle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>108.7 ± 4.5</td>
<td>348.6 ± 14.7</td>
<td>7.440 ± 0.024</td>
<td>31.3 ± 1.9</td>
<td>164.5 ± 3.0</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>107.0 ± 4.2</td>
<td>373.1 ± 19.1</td>
<td>7.436 ± 0.024</td>
<td>29.3 ± 1.8</td>
<td>176.4 ± 7.7</td>
</tr>
<tr>
<td>after infusion</td>
<td>102.4 ± 2.9</td>
<td>377.3 ± 14.7</td>
<td>7.425 ± 0.016</td>
<td>30.1 ± 2.7</td>
<td>174.2 ± 8.3</td>
</tr>
<tr>
<td>0.092 mg/kg TSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>before 3-VO</td>
<td>106.0 ± 3.2</td>
<td>368.6 ± 18.7</td>
<td>7.418 ± 0.020</td>
<td>32.9 ± 1.9</td>
<td>172.3 ± 7.5</td>
</tr>
<tr>
<td>during 3-VO &amp; infusion</td>
<td>106.1 ± 3.3</td>
<td>395.8 ± 17.3</td>
<td>7.417 ± 0.018</td>
<td>31.8 ± 1.7</td>
<td>184.1 ± 9.4</td>
</tr>
<tr>
<td>after infusion</td>
<td>103.9 ± 3.3</td>
<td>391.4 ± 14.6</td>
<td>7.431 ± 0.014</td>
<td>31.4 ± 1.1</td>
<td>170.3 ± 15.9</td>
</tr>
</tbody>
</table>

* Values shown are means ± SEs. No significant intergroup differences were observed for MABP, heart rate, blood pH, blood PCO₂, or blood PO₂.
during partial ischemia and by attenuating reperfusion-induced oxidative injury.

Conclusions

The protective actions of TSC represent a novel therapy based on the concept of “metabolic reflow,” which can operate under conditions of partial vascular perfusion. It will be of interest for future studies to evaluate the potential efficacy of this compound when applied in a delayed manner after the onset of ischemia. If TSC were to provide a similar protective effect under such conditions, it might also prove to be of value in the context of other forms of ischemic injury, such as transient ischemic attacks and stroke.

Disclosure

Dr. Gainer was a faculty member in the Department of Chemical Engineering at the University of Virginia during the performance of the studies described herein. He is now the chief scientific consultant for Diffusion Pharmaceuticals, LLC, which is developing trans-sodium crocetinate for clinical use.

This study was supported by grant no. NS057168 from the NIH/NINDS to Dr. Lee and grant no. T32 GM08328 from the NIH/NIGMS to Ryon Clarke and Dr. Lee.

Acknowledgments

The authors thank Mark Fitzgerald, Yi Wang, and Yu Cai for critical reading of the manuscript.

References

Neuroprotection by TSC


Portions of this work were presented in abstract form at the Society for Neuroscience Annual Meeting, San Diego, 2007. Please include this information when citing this paper: published online December 4, 2009; DOI: 10.3171/2009.10.JNS09562.

Address correspondence to: Kevin S. Lee, Ph.D., Department of Neuroscience, Room 5152, 409 Lane Road (MR4 Building), Charlottesville, Virginia 22908. email: ksl3h@virginia.edu.